BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...is a principal investigator at the Netherlands Cancer Institute and Oncode Institute, founded cell engineering company T-Cell Factory B.V....
BioCentury | Jun 8, 2015
Strategy

Juno's progressive thinking

...Sourasky Medical Center to develop CAR T cells with increased selectivity. In April, Kite purchased T-Cell Factory B.V....
...stock and up to €242.5 million ($256.2 million) in clinical, regulatory and sales milestones. The T-Cell Factory...
BioCentury | May 12, 2015
Company News

Juno acquires manufacturing play Stage

...Juno Therapeutics GmbH. Kite Pharma Inc. (NASDAQ:KITE), which also makes cell therapies for cancer, acquired T-Cell Factory B.V....
BioCentury | Apr 20, 2015
Company News

T-Cell Factory, Kite Pharma deal

...Cancer company Kite acquired T-Cell Factory for EUR20 million ($21.1 million) in cash and stock and up...
...T-Cell Factory will now be a subsidiary of Kite and will be renamed Kite Pharma EU. T-Cell Factory B.V....
BioCentury | Sep 25, 2001
Company News

GCOR licenses Integrated Genomics technology

Research product developer Genencor (GCOR) received access to three microbial gene sequencing technologies from Integrated Genomics (Chicago, Ill.). The technologies include Aspergillus niger genome sequence data, ERGO bioinformatics suite and Genome Explorer for regulatory pathway...
BioCentury | Nov 10, 1997
Politics, Policy & Law

Huam cloning, vaguely defined

OXFORD - Europe's oldest political organization, the Council of Europe, has adopted a protocol banning human cloning. The protocol, which would be added to the Convention on Human Rights and Bioethics, needs to be ratified by...
Items per page:
1 - 6 of 6
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...is a principal investigator at the Netherlands Cancer Institute and Oncode Institute, founded cell engineering company T-Cell Factory B.V....
BioCentury | Jun 8, 2015
Strategy

Juno's progressive thinking

...Sourasky Medical Center to develop CAR T cells with increased selectivity. In April, Kite purchased T-Cell Factory B.V....
...stock and up to €242.5 million ($256.2 million) in clinical, regulatory and sales milestones. The T-Cell Factory...
BioCentury | May 12, 2015
Company News

Juno acquires manufacturing play Stage

...Juno Therapeutics GmbH. Kite Pharma Inc. (NASDAQ:KITE), which also makes cell therapies for cancer, acquired T-Cell Factory B.V....
BioCentury | Apr 20, 2015
Company News

T-Cell Factory, Kite Pharma deal

...Cancer company Kite acquired T-Cell Factory for EUR20 million ($21.1 million) in cash and stock and up...
...T-Cell Factory will now be a subsidiary of Kite and will be renamed Kite Pharma EU. T-Cell Factory B.V....
BioCentury | Sep 25, 2001
Company News

GCOR licenses Integrated Genomics technology

Research product developer Genencor (GCOR) received access to three microbial gene sequencing technologies from Integrated Genomics (Chicago, Ill.). The technologies include Aspergillus niger genome sequence data, ERGO bioinformatics suite and Genome Explorer for regulatory pathway...
BioCentury | Nov 10, 1997
Politics, Policy & Law

Huam cloning, vaguely defined

OXFORD - Europe's oldest political organization, the Council of Europe, has adopted a protocol banning human cloning. The protocol, which would be added to the Convention on Human Rights and Bioethics, needs to be ratified by...
Items per page:
1 - 6 of 6